NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada (MDC). Each year MDC presents their esteemed Dr David Green Awards to groups and individuals who have shown exceptional commitment to improving the lives of Canadians affected by NMDs. We are honored to receive the Excellence in Service Delivery Award for 2024 and are excited to continue working with MDC and the entire Canadian neuromuscular community to fulfill our network mission to improve the care, research, and treatment of NMDs for all Canadians.
NMD4C Investigators Receiving a Dr. David Green Award
As an academic research network, we rely on the incredible team of investigators who are the driving force behind our work and are thrilled to see several NMD4C investigators receive individual awards recognizing their contributions to the neuromuscular community! Congratulations to Dr Jodi Warman Chardon, Dr Erin O’Ferrall, and Dr Cam-Tu Émilie Nguyen, who each received a Dr David Green Award:
Dr Jodi Warman-Chardon, recipient of the 2024 Dr George Karpati Award for Researcher of the Year
Dr Erin O’Ferrall, recipient of the Outstanding Healthcare Partner Award
Dr Cam-Tu Émilie Nguyen, recipient of the Rising Clinician/Researcher Award
Read the full news release from MDC to see the full list of award winners!.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.